Compare DGII & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DGII | HCM |
|---|---|---|
| Founded | 1985 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | 1796 |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.3B |
| IPO Year | 1995 | N/A |
| Metric | DGII | HCM |
|---|---|---|
| Price | $74.35 | $11.73 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 5 | 1 |
| Target Price | ★ $48.80 | $13.75 |
| AVG Volume (30 Days) | ★ 387.3K | 46.7K |
| Earning Date | 05-06-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.05 | N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $430,221,000.00 | N/A |
| Revenue This Year | $18.71 | $20.60 |
| Revenue Next Year | $7.22 | $15.62 |
| P/E Ratio | $120.25 | ★ $5.49 |
| Revenue Growth | ★ 1.46 | N/A |
| 52 Week Low | $30.69 | $9.77 |
| 52 Week High | $76.41 | $19.50 |
| Indicator | DGII | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 63.79 | 61.19 |
| Support Level | $64.19 | $9.77 |
| Resistance Level | N/A | $15.59 |
| Average True Range (ATR) | 2.62 | 0.29 |
| MACD | 0.27 | 0.23 |
| Stochastic Oscillator | 79.70 | 95.83 |
Digi International Inc is a Minnesota corporation that provides business and mission-critical Internet of Things (IoT) connectivity products and services. It operates through two segments: IoT Products & Services, which supports OEMs, enterprise, and government customers in deploying secure IoT connectivity solutions, and IoT Solutions, consisting of SmartSense and its Managed Network-as-a-Service (MNaaS) business offering wireless temperature and condition-based monitoring, employee task management, label printing, and other services. The company generates the majority of its revenue from the IoT Products & Services segment and mainly from the United States, with a presence in Europe, the Middle East and Africa, and the Rest of the world.
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.